Evidence map›Paper›PMID 39839672›Full record

ReviewFrontiers in cell and developmental biology2024

New insight in immunotherapy and combine therapy in colorectal cancer.

Kai Ji, Hang Jia, Zixuan Liu, Guanyu Yu, Rongbo Wen, Tianshuai Zhang, Zhiying Peng, Wenjiang Man, Yucheng Tian, Can Wang and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kai Ji *Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Hang Jia *Department of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zixuan Liu *Department of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Guanyu YuDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Rongbo WenDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Tianshuai ZhangDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Zhiying PengDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Wenjiang ManDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Yucheng TianDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Can WangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Qianlong LingDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Wei ZhangDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Leqi ZhouDepartment of Colorectal Surgery, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Mulin LiuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Bing ZhuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of immune checkpoint inhibitors (ICIs) in colorectal cancer (CRC) treatment marks a major breakthrough. These therapies have proven safer and more effective than traditional radiotherapy and targeted treatments. Immunotherapies like pembrolizumab, nivolumab, and ipilimumab have pioneered new treatment avenues, potentially improving patient outcomes and quality of life. Additionally, advances in immunotherapy have prompted detailed research into CRC therapies, especially those integrating ICIs with conventional treatments, providing new hope for patients and shaping future research and practice. This review delves into the mechanisms of various ICIs and evaluates their therapeutic potential when combined with radiotherapy, chemotherapy, and targeted therapies in clinical settings. It also sheds light on the current application and research involving ICIs in CRC treatment.

Indexed as

chemotherapycolorectal cancercombination therapyICISimmunomodulatoryradiotherapy

Identifiers

PMID39839672
PMCPMC11747282

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.